1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- Celgene Corp.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- MORE
Global Mycosis Fungoides Therapeutics Market: About this market
The mycosis fungoides therapeutics market analysis considers sales from small molecules and biologics types. Our analysis also considers the sales of mycosis fungoides therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost and easy availability of small molecules will play a significant role in the small molecules segment to maintain its market position. Also, our global mycosis fungoides therapeutics market report looks at factors such as special drug designations, recent drug approvals, and growing incidence of mycosis fungoides. However, slow progressive nature of the disease, dominance of alternative therapies, and stringent regulatory policies may hamper the growth of the mycosis fungoides therapeutics industry over the forecast period.
Global Mycosis Fungoides Therapeutics Market: Overview
Special drug designations
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. Most of the drugs being developed for the treatment of mycosis fungoides have been receiving special designations from regulatory bodies such as the US FDA and the EMA. Many of these drugs have received designations such as the Orphan drug designation and Breakthrough Therapy designation. Vendors who have received the Orphan drug designation for their drugs get certain regulatory and tax benefits. Similarly, the Breakthrough Therapy designation is granted by the US FDA to drugs that have displayed a superior efficacy and substantial treatment advantages over other drugs that are currently available in the market for the treatment of the same indication. Breakthrough therapy designation also confers vendors with a priority review status over other drugs that are being evaluated by the regulatory body. These factors will contribute to an increase in the sales of drugs to treat mycosis fungoides, fueling the mycosis fungoides therapeutics market to grow at a CAGR of over 6% during the forecast period.
Strong R&D of pipeline molecules
Various pharmaceutical and biotechnology companies are conducting research on developing therapeutics to capture the unmet need for highly effective therapeutics that can either provide long-term relief from the indication or cure the indication. To increase the customer base and remain competitive, vendors are developing highly effective biologics, targeted therapies, and small molecule-based therapies. As a result, the mycosis fungoides therapeutics market has been recording strong R&D of pipeline molecules. The expected launch of biologics will shift the therapeutic landscape for mycosis fungoides toward biologics, contributing to mycosis fungoides therapeutics market growth.
Competitive Landscape
With the presence of a few major players, the global mycosis fungoides therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading mycosis fungoides therapeutics manufacturers, that include Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence the market growth. This is to help companies strategize and leverage on all the forthcoming growth opportunities.
The mycosis fungoides therapeutics market analysis considers sales from small molecules and biologics types. Our analysis also considers the sales of mycosis fungoides therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost and easy availability of small molecules will play a significant role in the small molecules segment to maintain its market position. Also, our global mycosis fungoides therapeutics market report looks at factors such as special drug designations, recent drug approvals, and growing incidence of mycosis fungoides. However, slow progressive nature of the disease, dominance of alternative therapies, and stringent regulatory policies may hamper the growth of the mycosis fungoides therapeutics industry over the forecast period.
Global Mycosis Fungoides Therapeutics Market: Overview
Special drug designations
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. Most of the drugs being developed for the treatment of mycosis fungoides have been receiving special designations from regulatory bodies such as the US FDA and the EMA. Many of these drugs have received designations such as the Orphan drug designation and Breakthrough Therapy designation. Vendors who have received the Orphan drug designation for their drugs get certain regulatory and tax benefits. Similarly, the Breakthrough Therapy designation is granted by the US FDA to drugs that have displayed a superior efficacy and substantial treatment advantages over other drugs that are currently available in the market for the treatment of the same indication. Breakthrough therapy designation also confers vendors with a priority review status over other drugs that are being evaluated by the regulatory body. These factors will contribute to an increase in the sales of drugs to treat mycosis fungoides, fueling the mycosis fungoides therapeutics market to grow at a CAGR of over 6% during the forecast period.
Strong R&D of pipeline molecules
Various pharmaceutical and biotechnology companies are conducting research on developing therapeutics to capture the unmet need for highly effective therapeutics that can either provide long-term relief from the indication or cure the indication. To increase the customer base and remain competitive, vendors are developing highly effective biologics, targeted therapies, and small molecule-based therapies. As a result, the mycosis fungoides therapeutics market has been recording strong R&D of pipeline molecules. The expected launch of biologics will shift the therapeutic landscape for mycosis fungoides toward biologics, contributing to mycosis fungoides therapeutics market growth.
Competitive Landscape
With the presence of a few major players, the global mycosis fungoides therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading mycosis fungoides therapeutics manufacturers, that include Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence the market growth. This is to help companies strategize and leverage on all the forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Celgene Corp.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market characteristics analysis
Exhibit 06: Market segments
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Global mycosis fungoides therapeutics market pipeline: Overview
Exhibit 20: Global mycosis fungoides therapeutics market pipeline: Snapshot
Exhibit 21: Type - Market share 2018-2023 (%)
Exhibit 22: Comparison by type
Exhibit 23: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 25: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by type
Exhibit 28: Customer landscape
Exhibit 29: Customer landscape analysis
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendor landscape analysis
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Azurity Pharmaceuticals Inc. - Vendor overview
Exhibit 55: Azurity Pharmaceuticals Inc. - Business segments
Exhibit 56: Azurity Pharmaceuticals Inc. - Organizational developments
Exhibit 57: Azurity Pharmaceuticals Inc. - Key offerings
Exhibit 58: Azurity Pharmaceuticals Inc. - Key customers
Exhibit 59: Celgene Corp. - Vendor overview
Exhibit 60: Celgene Corp. - Business segments
Exhibit 61: Celgene Corp. - Organizational developments
Exhibit 62: Celgene Corp. - Geographic focus
Exhibit 63: Celgene Corp. - Key offerings
Exhibit 64: Celgene Corp. - Key customers
Exhibit 65: Eisai Co. Ltd. - Vendor overview
Exhibit 66: Eisai Co. Ltd. - Business segments
Exhibit 67: Eisai Co. Ltd. - Organizational developments
Exhibit 68: Eisai Co. Ltd. - Geographic focus
Exhibit 69: Eisai Co. Ltd. - Segment focus
Exhibit 70: Eisai Co. Ltd. - Key offerings
Exhibit 71: Eisai Co. Ltd. - Key customers
Exhibit 72: Helsinn Healthcare SA - Vendor overview
Exhibit 73: Helsinn Healthcare SA - Business segments
Exhibit 74: Helsinn Healthcare SA - Organizational developments
Exhibit 75: Helsinn Healthcare SA - Key offerings
Exhibit 76: Helsinn Healthcare SA - Key customers
Exhibit 77: Horizon Therapeutics Plc - Vendor overview
Exhibit 78: Horizon Therapeutics Plc - Business segments
Exhibit 79: Horizon Therapeutics Plc - Organizational developments
Exhibit 80: Horizon Therapeutics Plc - Geographic focus
Exhibit 81: Horizon Therapeutics Plc - Segment focus
Exhibit 82: Horizon Therapeutics Plc - Key offerings
Exhibit 83: Horizon Therapeutics Plc - Key customers
Exhibit 84: Kyowa Kirin Co. Ltd. - Vendor overview
Exhibit 85: Kyowa Kirin Co. Ltd. - Business segments
Exhibit 86: Kyowa Kirin Co. Ltd. - Organizational developments
Exhibit 87: Kyowa Kirin Co. Ltd. - Geographic focus
Exhibit 88: Kyowa Kirin Co. Ltd. - Segment focus
Exhibit 89: Kyowa Kirin Co. Ltd. - Key offerings
Exhibit 90: Kyowa Kirin Co. Ltd. - Key customers
Exhibit 91: Merck & Co. Inc. - Vendor overview
Exhibit 92: Merck & Co. Inc. - Business segments
Exhibit 93: Merck & Co. Inc. - Organizational developments
Exhibit 94: Merck & Co. Inc. - Geographic focus
Exhibit 95: Merck & Co. Inc. - Segment focus
Exhibit 96: Merck & Co. Inc. - Key offerings
Exhibit 97: Merck & Co. Inc. - Key customers
Exhibit 98: Seattle Genetics Inc. - Vendor overview
Exhibit 99: Seattle Genetics Inc. - Business segments
Exhibit 100: Seattle Genetics Inc. - Organizational developments
Exhibit 101: Seattle Genetics Inc. - Key offerings
Exhibit 102: Seattle Genetics Inc. - Key customers
Exhibit 103: Soligenix Inc. - Vendor overview
Exhibit 104: Soligenix Inc. - Business segments
Exhibit 105: Soligenix Inc. - Organizational developments
Exhibit 106: Soligenix Inc. - Segment focus
Exhibit 107: Soligenix Inc. - Key offerings
Exhibit 108: Soligenix Inc. - Key customers
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: List of abbreviations
Exhibit 117: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Small molecules - Market size and forecast 2018-2023
- Biologics - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
- Market drivers
- Market challenges
- Strong R&D of pipeline molecules
- Novel drug delivery system
- Increasing research funding
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Azurity Pharmaceuticals Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- Seattle Genetics Inc.
- Soligenix Inc.
- Takeda Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market characteristics analysis
Exhibit 06: Market segments
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Global mycosis fungoides therapeutics market pipeline: Overview
Exhibit 20: Global mycosis fungoides therapeutics market pipeline: Snapshot
Exhibit 21: Type - Market share 2018-2023 (%)
Exhibit 22: Comparison by type
Exhibit 23: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 25: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by type
Exhibit 28: Customer landscape
Exhibit 29: Customer landscape analysis
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendor landscape analysis
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Azurity Pharmaceuticals Inc. - Vendor overview
Exhibit 55: Azurity Pharmaceuticals Inc. - Business segments
Exhibit 56: Azurity Pharmaceuticals Inc. - Organizational developments
Exhibit 57: Azurity Pharmaceuticals Inc. - Key offerings
Exhibit 58: Azurity Pharmaceuticals Inc. - Key customers
Exhibit 59: Celgene Corp. - Vendor overview
Exhibit 60: Celgene Corp. - Business segments
Exhibit 61: Celgene Corp. - Organizational developments
Exhibit 62: Celgene Corp. - Geographic focus
Exhibit 63: Celgene Corp. - Key offerings
Exhibit 64: Celgene Corp. - Key customers
Exhibit 65: Eisai Co. Ltd. - Vendor overview
Exhibit 66: Eisai Co. Ltd. - Business segments
Exhibit 67: Eisai Co. Ltd. - Organizational developments
Exhibit 68: Eisai Co. Ltd. - Geographic focus
Exhibit 69: Eisai Co. Ltd. - Segment focus
Exhibit 70: Eisai Co. Ltd. - Key offerings
Exhibit 71: Eisai Co. Ltd. - Key customers
Exhibit 72: Helsinn Healthcare SA - Vendor overview
Exhibit 73: Helsinn Healthcare SA - Business segments
Exhibit 74: Helsinn Healthcare SA - Organizational developments
Exhibit 75: Helsinn Healthcare SA - Key offerings
Exhibit 76: Helsinn Healthcare SA - Key customers
Exhibit 77: Horizon Therapeutics Plc - Vendor overview
Exhibit 78: Horizon Therapeutics Plc - Business segments
Exhibit 79: Horizon Therapeutics Plc - Organizational developments
Exhibit 80: Horizon Therapeutics Plc - Geographic focus
Exhibit 81: Horizon Therapeutics Plc - Segment focus
Exhibit 82: Horizon Therapeutics Plc - Key offerings
Exhibit 83: Horizon Therapeutics Plc - Key customers
Exhibit 84: Kyowa Kirin Co. Ltd. - Vendor overview
Exhibit 85: Kyowa Kirin Co. Ltd. - Business segments
Exhibit 86: Kyowa Kirin Co. Ltd. - Organizational developments
Exhibit 87: Kyowa Kirin Co. Ltd. - Geographic focus
Exhibit 88: Kyowa Kirin Co. Ltd. - Segment focus
Exhibit 89: Kyowa Kirin Co. Ltd. - Key offerings
Exhibit 90: Kyowa Kirin Co. Ltd. - Key customers
Exhibit 91: Merck & Co. Inc. - Vendor overview
Exhibit 92: Merck & Co. Inc. - Business segments
Exhibit 93: Merck & Co. Inc. - Organizational developments
Exhibit 94: Merck & Co. Inc. - Geographic focus
Exhibit 95: Merck & Co. Inc. - Segment focus
Exhibit 96: Merck & Co. Inc. - Key offerings
Exhibit 97: Merck & Co. Inc. - Key customers
Exhibit 98: Seattle Genetics Inc. - Vendor overview
Exhibit 99: Seattle Genetics Inc. - Business segments
Exhibit 100: Seattle Genetics Inc. - Organizational developments
Exhibit 101: Seattle Genetics Inc. - Key offerings
Exhibit 102: Seattle Genetics Inc. - Key customers
Exhibit 103: Soligenix Inc. - Vendor overview
Exhibit 104: Soligenix Inc. - Business segments
Exhibit 105: Soligenix Inc. - Organizational developments
Exhibit 106: Soligenix Inc. - Segment focus
Exhibit 107: Soligenix Inc. - Key offerings
Exhibit 108: Soligenix Inc. - Key customers
Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: List of abbreviations
Exhibit 117: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Azurity Pharmaceuticals Inc.
- Celgene Corp.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- Seattle Genetics Inc.
- Soligenix Inc.
- Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
